Regeneron gets FDA approval for Libtayo, chemo combination for NSCLC
The approval was based on better survival results of Libtayo plus chemotherapy in comparison to chemotherapy alone in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Nov 22
The approval was based on better survival results of Libtayo plus chemotherapy in comparison to chemotherapy alone in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 22
Oyster Point owns the FDA-approved Tyrvaya, which is used for the treatment of dry eye disease, while Famy…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 22
Beyfortus is a long-acting antibody, indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Nov 22
Exelixis expects each of the licenced antibodies to have the potential to be turned into an ADC or…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Nov 22
As per the terms of the deal, CSL Seqirus will pay Arcturus $200m upfront and an additional $1.3bn…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Oct 22
The application was based on pivotal phase III data, which confirmed the vaccine's effectiveness against respiratory syncytial virus-related…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Oct 22
Vabysmo is the first and only medication that targets and inhibits two disease pathways involving Ang-2 and VEGF-A…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Oct 22
However, the CRDAC panel did not support and voted 11-5 against the drug to be used in patients,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Oct 22
The transaction is anticipated to close in the first quarter of 2023, subject to certain customary closing conditions,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Oct 22
The approval by the US regulator was based on the findings of the HIMALAYA phase 3 trial which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates